CW December 2002
Volume 11Issue Number 12 December 2002 ISSN 10593802 Capecitabine May Replace 5-FU in Combination Chemotherapy for Colorectal CancerCapecitabine (Xeloda, Roche) pills may soon replace 5-fluorouracil (5-FU) infusions in combination chemotherapy for colorectal cancer (CRC). New results from a landmark, multicenter phase II study of 96 metastatic CRC patients who take capecitabine and oxaliplatin (Eloxatin, Sanofi) as a first-line therapy show a greater than 50% response rate.
Go to Previous Page Go to Next Page Source & Additional Reading 20th Annual Chemotherapy Foundation Symposium. Purchase Downloadable Full-text PDF of Article: $10.00 Subscription is more cost effective than purchasing PDFs on-the-fly. Click here for details. Download Complete Issue CW December 2002Purchase Downloadable Full-text PDF of Complete Issue: $20.00 |
|
Member Login | Home | Offices | Subscribe | Glossary | Cancer Technologies | Contact Us
Adenine Press, 2066 Central Avenue, Schenectady, NY 12304 USA |
Re-initialize IP-based Login |
